<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Clinical Biochemist</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6C1BA1C-19BE-4D1F-BC94-CDFB2448695C"><gtr:id>B6C1BA1C-19BE-4D1F-BC94-CDFB2448695C</gtr:id><gtr:firstName>Satya</gtr:firstName><gtr:surname>Dash</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600414"><gtr:id>8FDB8F5A-BDF2-463A-9AE1-3946A1DAE085</gtr:id><gtr:title>Mutations in BDNF/TrkB and Obesity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0600414</gtr:grantReference><gtr:abstractText>Obesity, with its complications such as diabetes , heart attacks and possibly certain cancers, is one of the major health care problems facing the U.K. In most cases it results from a combination of environmental factors and multiple genes. Rarely, mutations in a single gene can cause obesity. It is by studying such cases that our understanding of the causes of obesity has improved. My sponsor?s laboratory recently found a mutation in a gene called NTRK2 in an 8 year old boy causing developmental problems and marked obesity. Our aim is to study other children with similar problems to see if they have similar mutations. We then propose to repeat the study in the more general population to see if small differences in this gene affect body weight. These studies are likely to significantly aid our understanding of this complex health problem</gtr:abstractText><gtr:technicalSummary>Obesity and its consequences are perhaps the major healthcare challenge in the developed world. Although common obesity is likely to be caused by a combination of environmental factors and multiple genes, studying monogenic causes improves our understanding of the molecular basis for this condition. Monogenic loss of function mutations in the leptin-melanocortin pathway are recognized causes of obesity. Recent evidence shows that deletions in brain derived growth factor (BDNF) and its receptor TrkB cause obesity and developmental delay in mouse models. This is thought to be secondary to impaired neuronal plasticity in the hypothalamus. BDNF treatment reverses obesity in melanocortin 4 receptor knockout mice suggesting that it works downstream of the leptin-melanocortin pathway.
My sponsor?s laboratory recently discovered a de novo heterozygous mutation in the TrkB gene in an 8 year old with severe obesity and developmental delay. In vitro studies suggested that this mutation results in impaired cell signalling. This mutation wasn?t found on screening 288 subjects out of a cohort of 450 with severe childhood obesity and developmental delay and/or behavioural problems in whom known monogenic causes and pleiotropic syndromes of obesity have been excluded.
The aim of the current study is to find establish the frequency of mutations in BDNF/TrkB in the remainder of the cohort of 450 children. The BDNF and TrkB genes will be sequenced directly as they are modest sized genes. Any variant found will be genotyped in a 100 control subjects of the same ethnic origin to exclude common ethnic specific polymorphisms. In those subjects with accessible family members, co-segregation of the variant with BMI and behavioural phenotype will be sought. Functional studies will be carried out in vitro to characterize any mutations found. To characterise TrkB mutations, PC12 cells will be stably transfected with wild type and mutant TrkB. These cells will be treated with BDNF and assd for neurite outgrowth by microscopy as well as cell survival. In addition, cell lysates will be Western blotted for phosphorylated Map kinase, PLC-? and Akt which are downstream signalling pathways of TrkB. To study mutations in BDNF in vitro, PC12 cells expressing wild type TrkB will be exposed to wild type and mutant BDNF and assessed for the same parameters as mutant TrkB.
In addition clinical studies will be carried out to characterise cases phenotypically. Parameters to be measured include height, weight, basal metabolic rate (via indirect calorimetry), food ingestion after an overnight fast and measurement of lean and fat mass using dual energy x-ray absorptiometry. Developmental milestones and psychological profiling using the Short Form of the British Ability Scales will be recorded. Magnetic resonant imaging will be used to visualise the hypothalamus and hippocampus.
Lastly population studies will be carried out to identify possible single nucleotide polymorphisms associated with altered body mass index.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>180390</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8CF73B59-93FD-4C17-B374-360DE5AC717F</gtr:id><gtr:title>Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent.</gtr:title><gtr:parentPublicationTitle>International journal of obesity (2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d4ad74ec5d9775195c9fc7fa2ed458f"><gtr:id>2d4ad74ec5d9775195c9fc7fa2ed458f</gtr:id><gtr:otherNames>Romeo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0307-0565</gtr:issn><gtr:outcomeId>EC2C1Ah4SjU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F82EABB-EE1B-4183-AD06-9AC6C1EE4D84</gtr:id><gtr:title>Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cf392162f27fb5f569cad74cad49d72"><gtr:id>2cf392162f27fb5f569cad74cad49d72</gtr:id><gtr:otherNames>Rubio-Cabezas O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>EGf2EkbSndY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C7E9764-52DF-4C18-B0F1-92DADE9D75AA</gtr:id><gtr:title>A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b32061dbcabfddafc235fd4e6c303aa3"><gtr:id>b32061dbcabfddafc235fd4e6c303aa3</gtr:id><gtr:otherNames>Dash S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Ht4tg2kMQGz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32748290-07D5-4F46-9D68-78E4D207B2B9</gtr:id><gtr:title>Analysis of TBC1D4 in patients with severe insulin resistance.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b32061dbcabfddafc235fd4e6c303aa3"><gtr:id>b32061dbcabfddafc235fd4e6c303aa3</gtr:id><gtr:otherNames>Dash S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>rTt1RjvpkF2</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600414</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>